RegMed Investors’ (RMi) closing bell analysis, our universe was cruising for a bruising

November 28, 2016 5:21pm

... It is still the old battle of the oversold versus the overbought

I’d be buying after big crashes, for the sector will swing to the upside

I say today what others won't, so you can do what others can't!

Pre-open indication’s tally:  3 hits and 4 miss

StemCells (STEM) – is officially Microbot Medical (MBOT) on Tuesday

There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.

U.S. stocks fell on Monday as financials lagged, while a massive post-election rally eased, and investors kept an eye on surging oil prices ahead of a key OPEC meeting.

The NASDAQ closed DOWN -30.11 or -0.56% to 5,368.81 and the DOW closed DOWN -54.24 or -0.28% to 19,097.90.

A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:   

• The open was negative with an A/DL of 16/24 and 3 flats;                     
• The mid-day stayed negative with an A/DL of 7/35 and 1 flat;
• The closing bell was negative with A/DL of 20/21 and 2 flats;

Henry’omics:

The stem, cell, gene and regenerative therapy (SCG&RT) sector opened negative, stayed negative at the mid-day and closed negative.

• From this morning’s investor’s letter, “it seems like “our” universe could go higher … However, expectation is not that great, if it exists at all!”

As the SCG&RT sector is following through by NOT doing ANY better today!

• As I had stated, low volume was Friday’s bottom line while Cellectis SA (CLLS +$0.64), Fate Therapeutics (FATE -$0.11), Histogenics (HSGX -$0.06), Opexa (OPXA +$0.24), ReNeuron (RENE.L +$0.28) and Vericel (VCEL +$0.10) experienced a surge in traffic.

Since the election, the Dow, S&P and NASDAQ have staged a three-week winning streak, while the small caps Russell 2000 closed -1.3% lower. The four indexes had set new record highs since Election Day.

I’d be taken ANY gains in December and DUMPING all pricing non-deliverers <lack of appreciation and on-coming financings> for tax considerations.

• The iShares Russell 2000 (IWM) indicated a negative pre- open of -0.31% and closed DOWN -1.30% while the iShares NASDAQ Biotechnology (IBB) did NOT indicate in the pre-open and closed DOWN -1.57%;
• The CBOE Volatility Index (VIX), widely considered the best gauge of fear in the market, traded higher, near 12.9.

At the close …

$ Gainers included

• Mesoblast (MESO +$0.25),
• ImmunoCellular (NYSEMKT: IMUC +$0.15),
• ReNeuron (RENE.L +$0.125),
• International Stem Cell (ISCO +$0.09) and
• Capricor (CAPR +0.09) contributed the few gains;

The biggest $ losers of the session were

• bluebird bio (BLUE -$3.30),
• Kite Pharma (KITE -$2.21),
• Bellicum (BLCM -$1.80),
• Spark Therapeutics (ONCE -$1.69) and
• Aduro Biotech (ADRO -$1.35)

The downside trend reflects a pricing trend range of:

• Monday’s decliners ranged from -0.91% <BCLI> to -9.94% <BTX> in 34 equities;
• Friday’s numbers were not tracked
• Thursday was Thanksgiving
• Wednesday’s decliners ranged from -2.17% <MESO> to -24.48% <JUNO> in 21 equities;
• Tuesday’s decliners ranged from – 0.16% <CAPR> to -28.57% <OPXA> in 26 equities;
• Last Monday’s decliners ranged from -0.58% <XON> to -15.49% <ADVM> in 15 equities;

The upside shows a pricing trend range of:

• Monday’s gainers ranged from +1.44% <CUR> to +5.96% <ISCO> in 7 equities;
• Friday was NOT tracked
• Thursday was Thanksgiving;
• Wednesday’s gainers ranged from + 0.01% <FCSC> to +11.90% <FATE> in 20 equities;
• Tuesday’s gainers ranged from +0.26% <VTGN> to +10.53% <FATE> in 14 equities;
• Last Monday’s gainers ranged from +0.14% <QURE> to +4831.3% (IMUC – after a reverse split> in 26 equities;

Wrap-up: anybody can read a paragraph … review the percentage changes per day in the week of the decliners and advancers while …

• Monday’s 7 gainers …
• Monday’s 34 decliners...

Pre-open indication’s tally:  3 hits (BSTG, VCEL and OPXA) and 4 miss (AGTC, FATE, HSGX and IMUC)

• Applied Genetic Technologies (AGTC) closed DOWN -$0.70 – miss;
• Biostage (BSTG) closed DOWN -$0.04 – hit;
• Histogenics (HSGX) closed DOWN -$0.05 – miss;
• ImmunoCellular (NYSEMKT: IMUC) closed UP +$0.15 – miss;
• Fate Therapeutics (FATE) closed DOWN -$0.09 – miss;
• Opexa (OPXA) closed DOWN -$0.07 – hit;
• Vericel (VCEL) closed DOWN -$0.05 – hit;

Percentage decliners:

• BioTime (NYSEMKT: BTX) -9.94%;
• Aduro Biotech (ADRO) -9.68%;
• Bellicum (BLCM) -8.72%;
• Sangamo (SGMO) -7.14%;
• Applied Genetic Technologies (AGTC) -7.07%

Percentage advancers:

• International Stem Cell (ISCO) +5.96%;
• Mesoblast (MESO) +5.47%;
• ImmunoCellular (NYSEMKT: IMUC) +5.17%;
• Reneuron (RENE.L) +4.55%;
• StemCells (STEM) +4.07%) – is officially Microbot Medical (MBOT) Tuesday

Flat:                                                                                                      

• Adverum (ADVM) at $2.95;
• Regenxbio (RGNX) at $22.25;

Review my fear gauge or the CBOE Volatility Index (VIX):

·         Monday traded near 12.9;

·         Friday traded near 12.3;

·         Thursday was a holiday;

·         Wednesday traded near 12.6;

·         Tuesday traded near 12.6;

·         Last Monday traded 12.5;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.